Institut für Mikrobiologie und Hygiene Regensburg
Franz-Josef-Strauß-Allee 11 - D-93053 Regensburg

Prof. Dr. Ralf Wagner

Telefon +49 (0) 941 - 944 6452
Telefax +49 (0) 941 - 944 6484
E-Mail Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein!



Unsere Projekte

Alle aktuellen Projekte unserer Arbeitsgruppe auf einen Blick:

Titel und Kurzbeschreibungen der Projekte

SynPeptide: Synthetic Biology for the Design and Production of Antibiotic Peptides

The Seventh Framework Program funded SYNPEPTIDE project (lead by Prof. Dr. Sven Panke, ETH Zürich) joins multiple European scientific groups to use synthetic biology for the design and production of novel peptide antibiotics. In the preceding SYNMOD project, molecular modules have been selected and recombined to obtain enhanced and new functions and a technology for high throughput screening...

Gerontoshield: Systems biology-driven approach to unravel and revert the mechanisms responsible for poor immune responses in the elderly

As people get older so does the immune system. This phenomenon of ‘immunosenescence’ leads to an increased susceptibility to infection and a lower vaccination success, for example against influenza. The GerontoShield project under the coordination of Prof. Guzmàn (Helmholtz Centre for Infection Research) aims to generate mathematical models of immune pathways from various data sources. To this end...

SYNMOD - Synthetic Biology to Obtain Novel Antibiotics and Optimized Production Systems

The ESF-funded SYNMOD project (lead by Prof. O. Kuipers, University of Groningen, NL) joins different european scientific groups to use synthetic biology for the design and production of novel antibiotic molecules from the group of lantibiotics. For this, more than 30 sub-molecular modules have been selected and will be recombined to obtain new functions. As there is so far no reliable molecular s...

PTVDC: Poxviurs T Cell Vaccine Discovery Consortium

Attenuated viruses are promising candidates as delivery system for HIV immunogens. Especially poxviruses are of interest due to their good immunological properties, like the avian poxvirus ALVAC used in the RV144 phase III Thai-Trial where a small protective effect was observed for the first time.In collaboration with the Centre Hospitalier Universitaire Vaudois (CHUV, Lausanne, Switzerland)...

Hector: Mechanisms of the immunological control of HIV replication in LTNP and HIV vaccine candidates derived thereof

Long term non progressors (LTNPs) are HIV-positive patients who develop AIDS after much longer times. In some cases, this is due mechanistically due to potent CTL responses (compare ForProtect above). To develop novel vaccine candidates potentially giving rise to CTL responses with increased breadth, epitope-enriched Gag, Pol and Nef immunogens are being designed using in silico algorithms. In par...

ForProtect: Computer-assisted design, production and analysis of HIV-specific T-cell immunogens

The protective phenotype of some HIV-positive long-term-non-progressors is associated with CTL responses against peptides presented on certain HLA alleles. As approaches to induce such responses by vaccination have failed so far, we want to generate epitope-enriched variants of the HIV Gag protein to achieve a broader immune response. For this, a computer-algorithm will be developed which (i) clas...

RepliVax: A Novel Replication Competent Flavivirus-based HIV Vaccine Platform, ie RepliVax®, as a Priming Component für Improving Antibody Response

Attenuated viral vectors used as delivery system for heterologous immunogens are supposed to be more potent inductors of immune responses than inactivated viruses or purified proteins. In collaboration with Sanofi Pasteur we are developing novel life-attenuated Flavivirus-based vectors for the delivery of HIV immunogens based on Sanofi's RepliVax® platform. For this, we are designing specially ada...

CUTHIVAC: Innovative design of HIV vaccines and delivery systems for transcutaneous immunization

Databases containing full-length sequences, experimentally identified T cell epitopes and protein structures from various HIV-1 isolates are readily available. Bioinformatic tools will be developed within this network to benefit from this vast amount of data in order to build novel GagPol variants representing universal HIV immunogens. For this, the proteins will be enriched with CD4- and CD8-epit...

IAVI: Design of soluble envelope proteins with enhanced trimer stability

The main objective of this project is the identification and selection of HIV envelope variants with high trimer stability and enhanced binding affinity of bNMABs such as PG9 and PG16. Therefore, in vitro display technologies developed in our group will be used to screen DNA libraries encoding HIV envelope protein variants. Selected candidates will be cloned in mammalian expression vectors and use...

VDAC:Lentiviral display to screen for improved Env immunogens

HI-viral particles are ideal vehicles to present combinatorial libraries of gp41 and gp140 derivatives in a membrane environment. Thus, we are generating lentiviral libraries displaying many variants of stable trimeric derivatives generated by various 'molecular evolution' approaches. Iterative rounds of panning with available and new NMabs at increasing stringency will select high affinity binder...

Mitarbeiter, News und Publikationen


Unsere News

Alle aktuellen News unserer Arbeitsgruppe auf einen Blick:

03. Apr. 2014 (15:27 Uhr)

Unsere Publikationen

Alle aktuellen Publikationen unserer Arbeitsgruppe auf einen Blick:

zum Seitenanfang